Cross-Trial Comparison Don'ts
from OncoPharm Hosted by John Bossaer
We all know we aren't supposed to make cross-trial comparisons, but it happens anyway. So, let's compare FLARUA2 (osimertinb + chemo) and the newly FDA-approved MARIPOSA regimen (lazertinib + amivantamab) to see what we can (and can't) take away from such a dangerous cross-trial comparison.
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 19 minutes long.
When was this OncoPharm episode published?
This episode was published on August 22, 2024.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.